FDA Brief

Warning letters Food

FDA warning letter to

Ar-Rahman Pharm LLC

High riskIssued Sep 7, 2021Posted Sep 9, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA and FTC cite Ar-Rahman Pharm for Diabetes Support sold with unapproved diabetes-treatment claims.

What happened

FDA reviewed the company's website and its Instagram and Facebook pages in August 2021 and found it takes orders for Diabetes Support, a dietary supplement. The sites claimed the product helps balance blood sugar, supports the pancreas, and helps manage diabetes. FDA says those claims make it an unapproved new drug and misbranded, and FTC also reviewed the sites and issued a cease and desist demand over unsubstantiated disease claims.

What FDA found

  1. Website and social media claims that Diabetes Support helps balance blood sugar and supports the pancreas show the product is intended to treat or prevent diabetes, which makes it a drug under the law.

    section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)]
  2. The product is not generally recognized as safe and effective for those uses, so it is an unapproved 'new drug' sold without FDA approval.

    sections 201(p), 301(d), and 505(a) of the FD&C Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The product lacks adequate directions for use because diabetes cannot be safely self-diagnosed or treated by a layperson without a licensed practitioner.

    section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Selling the misbranded product in interstate commerce violates the law.

    section 301(a) of the FD&C Act [21 U.S.C. 331(a)]
  5. FTC says the company advertised that a product can prevent, treat, or cure diabetes without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. ยง 41 et seq.

What FDA wants

FDA asks the company to notify FDA in writing within 15 working days of the specific steps taken to address the violations, including steps to prevent recurrence, and to include related documentation. If corrective actions cannot be completed in that time, the company must state why and when it will finish.

Who should pay attention

  • companies selling dietary supplements with disease-treatment claims
  • brands and contract manufacturers of diabetes-related supplements
  • marketing and compliance teams that manage supplement websites and social media

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk